Hyper IgD Periodic Fever Syndrome (HIDS) is a rare autoinflammatory disorder characterized by recurrent episodes of fever accompanied by various systemic symptoms. It falls under the broader category of periodic fever syndromes and is caused by mutations in the MVK gene, leading to mevalonate kinase deficiency.

What is Hyper IgD Periodic Fever Syndrome (HIDS)?
HIDS is a hereditary condition primarily affecting individuals of European descent, particularly those from the Netherlands. The syndrome often begins in infancy or early childhood and can persist throughout life.
Key Features of HIDS
- Recurrent febrile episodes
- Gastrointestinal disturbances
- Joint pain and swelling
- Enlarged lymph nodes
- Skin rashes
- Elevated immunoglobulin D (IgD) levels
Causes of Hyper IgD Periodic Fever Syndrome
HIDS is caused by mutations in the MVK gene, responsible for encoding the enzyme mevalonate kinase. This enzyme plays a crucial role in the isoprenoid biosynthesis pathway. Defective mevalonate kinase results in the accumulation of mevalonic acid, triggering inflammatory responses.
Genetic Inheritance
- HIDS is inherited in an autosomal recessive manner.
- Both parents must carry a mutated MVK gene for their child to be affected.
Symptoms of Hyper IgD Periodic Fever Syndrome
HIDS is characterized by episodes of fever that last 3 to 7 days and recur every 4 to 8 weeks. Common symptoms include:
- High fever (above 39°C or 102.2°F)
- Abdominal pain and vomiting
- Diarrhea
- Joint pain (arthralgia)
- Skin rashes (erythematous or urticarial lesions)
- Swollen lymph nodes
- Mouth ulcers
- Enlarged spleen and liver
Diagnosis of Hyper IgD Periodic Fever Syndrome
Accurate diagnosis involves a combination of clinical evaluation, family history, and laboratory testing. Key diagnostic steps include:
- Blood Tests: Elevated IgD levels (above 100 IU/mL) are a hallmark indicator.
- Genetic Testing: Identification of mutations in the MVK gene.
- Urinary Mevalonic Acid Analysis: Elevated mevalonic acid during febrile episodes.
Treatment Options for Hyper IgD Periodic Fever Syndrome
Although there is no definitive cure for HIDS, several treatment strategies help manage symptoms and improve the quality of life.
Common Treatments
- NSAIDs (e.g., ibuprofen): To reduce fever and inflammation.
- Corticosteroids: Effective during severe flare-ups.
- Colchicine: Helps reduce episode frequency.
- Biologic Agents (e.g., anakinra, canakinumab): Control systemic inflammation.
- Statins: Some patients may benefit from statins to reduce mevalonic acid buildup.
Lifestyle Management and Coping Strategies
While HIDS cannot be entirely prevented, adopting certain strategies can reduce symptom severity:
- Maintain a Healthy Diet: Anti-inflammatory foods may help.
- Stress Management: Stress can trigger flare-ups.
- Regular Medical Monitoring: Frequent checkups help track symptom patterns.
Prognosis of Hyper IgD Periodic Fever Syndrome
With proper management, individuals with HIDS can lead relatively normal lives. The frequency and severity of episodes tend to decrease with age, though some residual inflammation may persist.
FAQs:
What triggers HIDS flare-ups?
Common triggers include stress, infections, vaccinations, and physical exertion.
Is Hyper IgD Syndrome life-threatening?
While HIDS itself is not fatal, severe inflammatory responses may increase the risk of complications if left untreated.
Can adults develop HIDS?
Most cases present in childhood; however, undiagnosed individuals may experience symptoms in adulthood.
Is genetic counseling recommended for HIDS?
Yes, genetic counseling is advisable for affected families to assess the risk of passing the condition to future generations.
Are there any dietary recommendations for HIDS patients?
A balanced diet rich in anti-inflammatory foods, such as omega-3 fatty acids, may help reduce flare-ups.
Hyper IgD Periodic Fever Syndrome is a complex yet manageable condition. Early diagnosis, appropriate treatment, and lifestyle adjustments can significantly improve patient outcomes. Consulting with healthcare professionals for personalized care strategies remains essential.